KLF5 UPREGULATION IS A COMMON EVENT IN CHOLANGIOCARCINOMA, ACTING AS AN ONCOGENE AND CONSTITUTING A BAD PROGNOSTIC FACTOR

Pedro M. Rodrigues  ^{1, 2, 3}     Oihane Erice     Ana Landa-Magdalena     Nuno André Paiva     Maite García Fernandez-Barrena  ⁴     Paula Olaizola  ^{2, 1}     Ainhoa Lapitz  ^{2, 1}     Irene Olaizola     Colm J. O'Rourke  ⁵     Santiago Iturbe-Rey     Jesper B. Andersen     Diego F. Calvisi  ⁶     Mikel Azkargorta  ⁷     Felix Elortza     Ibai Goicoechea  ⁸     Charles H. Lawrie  ^{8, 9}     Luis Bujanda Fernández de Piérola  ^{2, 1}     María Jesús Perugorria  ^{2, 10, 11}     Jesús M. Bañales  ^{2, 12, 13    
1} Biodonostia Health Research Institute, San Sebastian, Spain
² National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, “Instituto de Salud Carlos III”), Madrid, Spain
³ IKERBASQUE, Basque Foundation for Science, Bilbao, Spai
⁴ Division of Hepatology, CIMA-University of Navarra, Pamplona, Spain
⁵ Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
⁶ Institute of Pathology, University of Regensburg, Regensburg, Germany
⁷ Proteomics Platform, CIC bioGUNE, CIBERehd, ProteoRed-ISCIII, Bizkaia Science and Technology Park, Derio, Spain
⁸ Molecular Oncology group, Biodonostia Research Institute, San Sebastian,, San Sebastian, Spain
⁹ Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
¹⁰ Department of Medicine, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain
¹¹ Bio
¹² IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
¹³ Department of Biochemistry and Genetics, School of Science

Topic
Hepatobiliary

Session
Oncology, transplantation and encephalopathy (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)